This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

PENMENVY Logo

Prescribing Information

Coding for PENMENVY

Here you’ll find vaccine product codes and some common administration codes associated with immunization using PENMENVY. Select another vaccine here.

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

Description: PENMENVY is supplied as 2 components for reconstitution: a vial of Lyophilized MenACWY Component (powder) and a prefilled Tip-Lok syringe (Luer Lock syringe) of MenB Component (liquid). Both components must be combined before use to form a single dose (approximately 0.5 mL) of PENMENVY. Tip-Lok syringes, packaged without needles, are to be used with Luer Lock-compatible needles. The tip cap and rubber plunger of the prefilled syringe and the stopper of the vial are not made with natural rubber latex.1

Dosage: Approximately 0.5 mL1

Coding for PENMENVY

CPT Code

90624

ICD-10-CM Code2*

Z23
MVX Code3 SKB

NDCs† (Supplied as an outer package of 10 doses)

Outer carton

NDC 58160-757-15

10 vials of Lyophilized MenACWY Component (powder)

NDC 58160-730-03

10 prefilled syringes of MenB Component (liquid)  

NDC 58160-750-03
Lightbulb icon

Tip

To promote accuracy, always consult the most current Prescribing Information or product packaging when documenting NDCs.

PENMENVY CPT Code – Immunization Administration Codes5‡

90460:

Immunization administration through 18 years of age via any route of administration, with counseling by physician or other qualified health care professional; first or only component of each vaccine or toxoid administered

+90461:

 

Each additional vaccine or toxoid component administered (List separately in addition to code for primary procedure)

90471:

Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections); 1 vaccine (single or combination vaccine/toxoid)

+90472:

 

Each additional vaccine (single or combination vaccine/toxoid) (List separately in addition to code for primary procedure)

Lightbulb icon

Tip

If reporting multiple vaccine administrations given to a patient through age 18 on the same date along with counseling by a qualified healthcare professional, report one administration code (90460) for each vaccine administered.

If a vaccine has multiple components, then 90460 should be reported once in conjunction with 90461 for each additional vaccine/toxoid component contained within that vaccine.6

Diagnosis Codes

Z23 is the ICD-10-CM code used when reporting an encounter for immunization for all vaccines given within the encounter. In some instances, additional ICD-10-CM coding may be needed. 

See all code types

GSK Codes Summary Sheet

Get a PDF of the most current CPT, CVX, MVX, and NDC codes for GSK vaccines.

Download

Questions?

Find answers to frequently asked questions, along with additional resources, to guide you to the information you need.

Get help

  •   *ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.2
  •   †Note that some payers require an 11-digit NDC, which involves adding a "0" immediately after the first hyphen in each GSK NDC.7 For example, when reporting NDC 58160-820-11 to TRICARE, it becomes NDC 58160-0820-11.
  •    ‡Adapted from the American Medical Association, CPT 2024 Professional Edition, Current Procedural Terminology (CPT), 2023.

References:

  1. Prescribing Information for PENMENVY.
  2. 2024 ICD-10-CM official guidelines for coding and reporting. Centers for Medicare and Medicaid Services. Updated April 1, 2024. Accessed January 2, 2025. https://www.cms.gov/files/document/fy-2024-icd-10-cm-coding-guidelines-updated-02/01/2024.pdf
  3. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. Centers for Disease Control and Prevention. Accessed January 2, 2025. https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx
  4. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. Centers for Disease Control and Prevention. Accessed January 2, 2025. https://www2a.cdc.gov/vaccines/IIS/IISStandards/downloads/cvx_list.pdf
  5. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listing) long descriptors. American Medical Association. Updated December 30, 2024. Accessed January 2, 2025. https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf
  6. Bright futures coding for pediatric preventive care 2022. American Academy of Pediatrics. Accessed January 2, 2025. https://downloads.aap.org/AAP/PDF/Coding%20Preventive%20Care.pdf
  7. Office injectable guidelines, National Drug Code (NDC) pricing and filing tips. Humana Military. Accessed January 2, 2025. https://www.humanamilitary.com/provider/claims/injectables#nucleustabs-ee21c6fea3-item-098209c56a-tab

Please note that this website is provided for informational purposes only and is not intended to serve as comprehensive training on medical billing and coding. Additional training on medical coding may be required. The information on this website is believed to be accurate as of the date of publication. Users should independently verify accuracy.

Healthcare providers are responsible for making the ultimate decision on when to use a specific product based on clinical recommendations and how to bill for products and related services rendered. Consult third-party insurers' guidelines for specific information regarding the billing and reporting of services rendered.

Indication

PENMENVY is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroups A, B, C, W, and Y in individuals 10 through 25 years of age.

Important Safety Information for PENMENVY

  • Do not administer PENMENVY to individuals with a severe allergic reaction (e.g., anaphylaxis) to a previous dose of PENMENVY, to any component of this vaccine, or to any other diphtheria toxoid-containing vaccine
  • Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following the administration of PENMENVY
  • Syncope (fainting) has occurred in association with administration of PENMENVY. Procedures should be in place to avoid injury from fainting
  • Vaccination with PENMENVY may not protect all vaccine recipients and may not provide protection against all meningococcal serogroup B strains
  • Immunocompromised persons, including those receiving immunosuppressive therapy, may have reduced immune responses to PENMENVY
  • Individuals with certain complement deficiencies and individuals receiving treatment that inhibits terminal complement activation are at increased risk for invasive disease caused by N. meningitidis, including disease caused by serogroups A, B, C, W, and Y, even if they develop antibodies following vaccination with PENMENVY
  • Guillain-Barré syndrome (GBS) has been reported in temporal relationship following administration of a U.S.-licensed meningococcal quadrivalent polysaccharide conjugate vaccine. The decision by the healthcare professional to administer PENMENVY to persons with a history of GBS should take into account the expected benefits and potential risks
  • The most commonly reported (≥10%) solicited adverse reactions in individuals aged 10 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (92% and 88%), fatigue (51% and 42%), headache (42% and 36%), myalgia (15% and 12%), nausea (15% and 10%), erythema (13% and 12%), and swelling (13% and 12%). The most commonly reported (≥10%) solicited adverse reactions in MenACWY conjugate vaccine-experienced individuals aged 15 through 25 years after Dose 1 and Dose 2, respectively, were pain at the injection site (80% and 74%), headache (41% and 33%), fatigue (40% and 33%), myalgia (15% and 13%), and nausea (15% and 12%)



Please see full Prescribing Information for PENMENVY.